Skip to content

Harmony Biosciences Holdings, Inc. HRMY In Process Research And Development Acquired

In Process Research And Development Acquired at other companies

Digi International logo
Digi InternationalDGII
$300K
DJT
Trump Media & Technology GroupDJT
$8.4M-33.1%
Photronics logo
PhotronicsPLAB
$2.82M-31.0%
ADMA Biologics logo
ADMA BiologicsADMA
$2.6M+214%
Quantum Computing Inc. logo
Quantum Computing Inc.QUBT
$6.97M+133%
Rumble, Inc. logo
Rumble, Inc.RUM
$5.74M+19.9%

Other financials

Income statement

See full
Revenue$215.4M+16.6%
Gross profit$170.9M+11.9%
Operating income$37.3M-33.7%
Net income$32.5M-28.7%
EPS (diluted)$0.55-29.5%

Balance sheet

See full
Cash & equivalents$589.4M+20.5%
Total debt$164.6M-7.2%
Total equity$910.3M+26.3%
Total assets$1.3B+20.5%

Cash flow

See full
Operating cash flow$27.8M-18.3%
CapEx$107.0K-79.1%
Free cash flow$126.0M+67.9%

Valuation

See full
Market cap$1.99B-14.9%

Profitability

See full
Gross margin76.5%-1.8pp
Operating margin21.1%-5.1pp
Net margin16.2%-4.3pp
FCF margin40.1%+9.5pp

Returns & leverage

See full
Return on equity17.9%-6.9pp
Debt / equity0.2×-0.1×
Current ratio3.6×-0.1×

Where this comes from

Reported directly by Harmony Biosciences Holdings, Inc. in its filing.

Tagged under the XBRL concept hrmy:InProcessResearchAndDevelopmentAcquired.

The official record: Harmony Biosciences Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Harmony Biosciences Holdings, Inc.'s in process research and development acquired.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Harmony Biosciences Holdings, Inc.'s in process research and development acquired?
Harmony Biosciences Holdings, Inc. (HRMY) reported in process research and development acquired of $32M in Q1 2026.
What does in process research and development acquired mean?
This reflects the value assigned to research and development projects acquired through business combinations or asset acquisitions that have not yet reached technological feasibility. It represents a significant capital allocation toward future growth and pipeline expansion. Monitoring this helps investors assess the company's commitment to external innovation versus internal development.